Novel Treatment for Anemia and Polycythemia: AVPR1B Molecules Modulating Erythropoiesis

Anemia can be caused by chronic diseases, chemotherapy, or radiation. Erythropoietin is commonly used to stimulate red blood cell production for anemia treatment, but it takes about a week to manifest its clinical effect. The subject invention describes the arginine vasopressin receptor 1B (AVPR1B) stimulatory molecules that can be used to stimulate hematopoietic stem cell proliferation. Preliminary results from animal studies suggest that the number of red blood cells and their precursors significantly increased on day 2 following AVP administration, an onset time much faster than erythropoietin. The AVPR1B stimulatory molecules can be used to jumpstart the system and erythropoietin can be used to sustain the effect. In addition, the AVPR1B inhibitory molecules can be used to suppress hematopoietic stem cell proliferation to treat polycythemia (overproduction of red blood cells).

Potential Commercial Applications: Competitive Advantages:
  • Treatment of anemia caused by chronic diseases, chemotherapy, or radiation.
  • Anemia patients who do not respond to erythropoietin.
  • Polycythemia treatment.
  • AVPR1B stimulatory molecules act faster than the commonly used erythropoietin for anemia treatment.

Development Stage:
  • Early-stage
  • In vivo data available (animal)


Eva Mezey (NIDCR)  ➽ more inventions...

Balazs Mayer

Krisztian Nemeth

Miklos Krepuska (NIDCR)  ➽ more inventions...

Intellectual Property:
PCT Pat: 10,172,911 issued 2019-01-08
US Application No. 61/885,258 filed on 2013-10-01
US Application No. 15/022,531 filed on 2016-03-16

Collaboration Opportunity:

The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize treatment for anemia and polycythemia. For collaboration opportunities, please contact David Bradley, Ph.D. at

Licensing Contact:
Vladimir Knezevic, M.D.
Phone: 301.443.5560

OTT Reference No: E-619-2013-0
Updated: Aug 6, 2015